Invokana Lawsuit Update
There is a recent development in the Invokana lawsuit against the manufacturer, Janssen Pharmaceutical, a subsidiary of Johnson & Johnson. The company netted almost $1 billion in profits from Invokana in 2016 alone.
The Judicial Panel on Multidistrict Litigation (JPMDL) issued an order to consolidate dozens of Invokana (canagliflozin) diabetic ketoacidosis (DKA) and kidney damage lawsuits to New Jersey federal court. The Panel transferred almost 100 Invokana and Invokamet lawsuits from districts in Illinois, Kentucky, Missouri, Minnesota, Virginia and West Virginia to the District of New Jersey before U.S. District Judge Brian R. Martinotti.
The JPMDL selected the District of New Jersey because this is where Janssen Pharmaceuticals has its headquarters. The JPMDL found many witnesses and relevant documents at this location. In addition, 37 other Invokana cases are already filed in New Jersey.
This ruling comes after a hearing where the JPMDL said it found that the Invokana cases involved common questions of fact, and centralization will serve the convenience of the parties.
Also in this Invokana lawsuit, the JPMDL identifies the common issues with Invokana. These were whether Invokana causes diabetic ketoacidosis and kidney injury along with questions concerning the development, testing, regulatory history, promotion and labeling of the drug.
Other Health Risks Identified in Invokana Lawsuit
In addition to diabetic ketoacidosis, plaintiffs said Invokana caused them to suffer blood clots, strokes, and other kidney injuries. The FDA approved the medication in 2013, and only two years later, the organization ordered the manufacturer to add diabetic ketoacidosis to the warning label.
Unfortunately, the additional health risks keep mounting. In 2015, the FDA warned Invokana could turn common urinary tract infections into serious, potentially life-threatening blood and kidney infections.
Next Steps in Invokana Lawsuit
The next step in this MDL will be pretrial proceedings before Judge Martinotti.
The nationally regarded attorneys at The Michael Brady Lynch Firm have extensive expertise in pharmaceutical and complex litigations. The Michael Brady Lynch Firm is currently at the forefront of not just this litigation but litigations representing users of Viagra, Cialis and Levitra who have been diagnosed with melanoma, Onglyza heart failure complications, Essure birth control complications and those who have suffered internal bleeding/hemorrhaging associated with the use of the drugs Pradaxa and Xarelto. We have recovered over $200 million in recoveries and verdicts on behalf of our clients.
- FDA Strengthens Invokana’s Label to Reflect Severe Kidney Damage
- The Michael Brady Lynch Firm Files 2nd Invokana Ketoacidosis Lawsuit